Last edition
News about " Phase 3 HARMONi-GI1 study"
Akeso's Ivonescimab Receives Priority Review in China for Biliary Tract Cancer
Akeso's ivonescimab has received Priority Review from China's NMPA for first-line treatment of locally advanced or metastatic biliary tract cancer.
Phase 3 HARMONi-GI1 Study | 06/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members